Request Demo
Last update 30 Oct 2025
AVID-100
Last update 30 Oct 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms AVID 100 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Boost your research with our ADC technology data.
login
or
Sequence Code 13028137L
Sequence Code 13351331H
Related
1
Clinical Trials associated with AVID-100NCT03094169
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
100 Clinical Results associated with AVID-100
Login to view more data
100 Translational Medicine associated with AVID-100
Login to view more data
100 Patents (Medical) associated with AVID-100
Login to view more data
100 Deals associated with AVID-100
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Feb 2017 | |
| EGFR positive Non-squamous non-small cell lung cancer | Phase 2 | United States | 01 Feb 2017 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 2 | United States | 01 Feb 2017 | |
| Squamous non-small cell lung cancer | Phase 2 | United States | 01 Feb 2017 | |
| Triple Negative Breast Cancer | Phase 2 | United States | 01 Feb 2017 | |
| Breast Cancer | Phase 2 | - | - | |
| Squamous Cell Carcinoma | Phase 2 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03094169 (AACR2019) Manual  | Phase 1/2 | - | lvmimetdat(nlukzpzsdb) = G3 asymptomatic lipase elevation, G4 reversible thrombocytopenia owjpgzmzik (ttpxdkkjmf ) View more | Positive | 01 Jul 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free